-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ISZM4ppaf9ACl5fQr5/RG1IAyDx2iAUwiyi+ruhPqgzXZHVLjO262wTCI02MYUYE fM3Ufex42JARZQR753JC3g== 0000950005-97-001006.txt : 19971219 0000950005-97-001006.hdr.sgml : 19971219 ACCESSION NUMBER: 0000950005-97-001006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 19971218 ITEM INFORMATION: FILED AS OF DATE: 19971218 SROS: NONE FILER: COMPANY DATA: COMPANY CONFORMED NAME: LYNX THERAPEUTICS INC CENTRAL INDEX KEY: 0000913275 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 943161073 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-22570 FILM NUMBER: 97740295 BUSINESS ADDRESS: STREET 1: 3832 BAY CENTER PL CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 5106709300 MAIL ADDRESS: STREET 1: 3832 BAY CENTER PLACE CITY: HAYWARD STATE: CA ZIP: 74545 8-K 1 FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 1997 Lynx Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3161073 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 0-22570 (Commission File Number) 3832 Bay Center Place Hayward, CA 94545 (Address of principal executive offices) (Zip Code) (510) 670-9300 (Registrant's telephone number, including area code) Total number of pages: 4 Page 1 of 4 Item 5. Other Events To demonstrate compliance with the requirements of the National Association of Securities Dealers in connection with the Company's proposed Nasdaq National Market listing application, attached hereto as Exhibits 99.1 and 99.2 are the Company's unaudited Condensed Consolidated Balance Sheet and Condensed Consolidated Statement of Operations for the period ended November 30, 1997. Item 7. Financial Statements and Exhibits (a) Financial statements of businesses acquired none (b) Pro forma financial information none (c) Exhibits 99.1 Lynx Therapeutics, Inc. unaudited Condensed Consolidated Balance Sheet for the period ended November 30, 1997 99.2 Lynx Therapeutics, Inc. unaudited Condensed Consolidated Statement of Operations for the eleven months ended November 30, 1997 Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lynx Therapeutics, Inc. ----------------------------------- (Registrant) December 18, 1997 /s/ Edward C. Albini - --------------------------- ----------------------------------- (Date) Edward C. Albini Chief Financial Officer (Principal Financial and Accounting Officer) Page 2 of 4 EX-99.1 2 CONDENSED CONSOLIDATED BALANCE SHEET Exhibit 99.1 Lynx Therapeutics, Inc. CONDENSED CONSOLIDATED BALANCE SHEET (In thousands) November 30, 1997 -------- (Unaudited) Assets Current assets: Cash and cash equivalents $ 11,887 Short-term investments 14,279 Accounts receivable 110 Other current assets 181 -------- Total current assets 26,457 Property and equipment: Leasehold improvements 3,790 Laboratory and other equipment 3,524 -------- 7,314 Less accumulated depreciation and amortization (3,475) -------- Net property and equipment 3,839 Notes receivable from employees 205 -------- $ 30,501 ======== Liabilities and stockholders' equity Current liabilities: Accounts payable $ 147 Accrued compensation 291 Accrued professional fees 149 Deferred revenue from related parties - current 2,521 Other accrued liabilities 374 -------- Total current liabilities 3,482 Deferred revenue from related parties - long-term 0 Other noncurrent liabilities 176 Stockholders' equity: Preferred stock 27,189 Common stock 42,702 Notes receivable from stockholders (460) Deferred compensation (1,513) Unrealized gain on marketable securities (1) Accumulated deficit (41,074) -------- Total stockholders' equity 26,843 -------- $ 30,501 ======== Page 3 of 4 EX-99.2 3 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.2 Lynx Therapeutics, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) Eleven Months Ended November 30, 1997 -------- Net revenues: Revenues from collaborative arrangements with related parties $ 3,908 Other revenues 294 -------- Total revenues 4,202 Operating expenses: Research and development 12,556 General and administrative 1,792 -------- Total operating expenses 14,348 -------- Income/(loss) from operations (10,146) Interest income 591 -------- Net income/(loss) $ (9,555) ======== Net income/(loss) per share $ (2.60) ======== Shares used in per share computation 3,675 ======== -----END PRIVACY-ENHANCED MESSAGE-----